Triple Analysis: Leukemia, Angiogenesis and Antibodies
BioSeeker Group AB
January 30, 2012 4795 Pages - SKU: BIOS6796167
|
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.This part is based on the following publication:A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market
Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.This part is based on the following publication:Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Part III: Antibodies
The cancer antibody drug report part comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications. This part is based on the following publication:
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
|
- Key Topics Covered:
- Part I: Leukemia
- 5.1 The Scope of this Report 29
- 6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
- 8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
- 9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
- 11 Disclaimer 1130
- 12 Drug Index 1131
- 13 Company Index 1140
- Figures: Includes 6 Figures
- Tables: Includes 253 Tables
- Total Number of Pages: 1,147
- Part II: Angiogenesis
- 5.1 The Scope of this Report 37
- 6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
- 8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
- 9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
- 12 Drug Index 1687
- 13 Company Index 1697
- Figures: Includes 7 Figures
- Tables: Includes 310 Tables
- Total Number of Pages: 1,704
- Part III: Antibodies
- 5.1 The Scope of this Report 35
- 6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (255 Drug Targets) 39-430
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug Targets Strategies and 531 Antibody Drugs) 431-768
- 8 Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications) 769-893
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531 Antibody Drugs) 894-1,916
- 10 Disclaimer 1917
- 11 Drug Index 1918
- 12 Company Index 1934
- Figures: Includes 5 Figures
- Tables: Includes 347 Tables
- Total Number of Pages: 1,944
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
